HRP20140586T1 - Peptidi za lijeäśenje beta-amiloidoze - Google Patents
Peptidi za lijeäśenje beta-amiloidoze Download PDFInfo
- Publication number
- HRP20140586T1 HRP20140586T1 HRP20140586AT HRP20140586T HRP20140586T1 HR P20140586 T1 HRP20140586 T1 HR P20140586T1 HR P20140586A T HRP20140586A T HR P20140586AT HR P20140586 T HRP20140586 T HR P20140586T HR P20140586 T1 HRP20140586 T1 HR P20140586T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- amino acid
- acid sequence
- peptide
- use according
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 9
- 206010002022 amyloidosis Diseases 0.000 title claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 2
- 206010002023 Amyloidoses Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000001413 amino acids Chemical group 0.000 claims 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 235000018417 cysteine Nutrition 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 208000032859 Synucleinopathies Diseases 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Claims (17)
1. Uporaba barem jednog spoja koji sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine: SEFKHG(C), TLHEFRH(C), ILFRHG(C), TSVFRH(C), SQFRHY(C), LMFRHN(C), SPNQFRH(C), ELFKHHL(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), YEFRHAQ(C) i TEFRHKA(C), naznačena time, da je za proizvodnju lijeka za sprečavanje i/ili liječenje B-amiloidoze.
2. Uporaba barem jednog spoja koji sadrži sljedeću aminokiselinsku sekvencu:
X1RX2DX3(X4)n(X4)m(X6)o (formula I),
naznačena time, da
X1 je izoleukin (I) ili valin (V),
X2 je triptofan (W) ili tirozin (Y),
X3 je treonin (T), valin (V), alanin (A), metionin (M), glutamin (Q) ili glicin (G),
X4 je prolin (P), alanin (A), tirozin (Y), serin (S), cistein (C) ili glicin (G),
X5 je prolin (P), leukin (L), glicin (G) ili cistein (C),
X6 je cistein (C), a
n, m i o su, međusobno neovisno, 0 ili 1,
dok spomenuti spoj ima kapacitet vezivanja na protutijelo koje je specifično za epitop od amiloid-beta-peptida (Aβ), koji sadrži aminokiselinsku sekvencu EFRHDSGY i/ili pEFRHDSGY, pri čemu je ta uporaba za proizvodnju lijeka za sprečavanje i/ili liječenje β-amiloidoze.
3. Uporaba prema zahtjevu 2, naznačena time, da spoj sadrži peptid koji ima aminokiselinsku sekvencu odabranu iz skupine koju čine: IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C) i IRWDGG(C).
4. Uporaba barem jednog spoja koji sadrži sljedeću aminokiselinsku sekvencu
EX1WHX2X3(X4)n(X5)m (formula II),
naznačena time, da
X1 je valin (V), arginin (R) ili leukin (L),
X2 je arginin (R) ili glutaminska kiselina (E),
X3 je alanin (A), histidin (H), lizin (K), leukin (L), tirozin (Y) ili glicin (G),
X4 je prolin (P), histidin (H), fenilalanin (F) ili glutamin (Q) ili cistein,
X5 je cistein (C), i n i m su međusobno neovisno 0 ili 1,
dok spomenuti spoj ima kapacitet vezivanja na protutijelo koje je specifično za epitop od amiloid-beta-peptida (Aβ), koji sadrži aminokiselinsku sekvencu EVHHQKL, pri čemu je ta uporaba za proizvodnju lijeka za sprečavanje i/ili liječenje β-amiloidoze.
5. Uporaba prema zahtjevu 4, naznačena time, da spoj sadrži peptid koji ima aminokiselinsku sekvencu odabranu iz skupine koju čine: EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRC(C), EVWHRH(C) i ERWHEK(C), poželjno EVWHRHQ(C), WRWHEKH(C), EVWHRLQ(C), ELWHRYP(C) i ELWHRAF(C).
6. Uporaba barem jednog spoja koji sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine: QDFRHY(C), SEFKHG (C), TSFRHG (C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHG(C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), NELRHST(C), GEMRHQP(C), DTYFPRS(C), VELRHSR(C), YSMRHDA(C), AANYFPR(C), SPNQFRH(C), SSSFFPR(C), EDWFFWH(C), SAGSFRH(C), QVMRHHA(C), SEFSHSS(C), QPNLFYH(C), ELFKHHL(C), TLHEFRH(C), ATFRHSP(C), APMYFPH(C), TYFSHSL(C), HEPLFSH(C), SLMRHSS(C), EFLRHTL (C), ATPLFRH (C), QELKRYY(C), THTDFRH(C), LHIPFRH(C), NELFKHF(C), SQYFPRP(C), DEHPFRH(C), MLPFRHG(C), SAMRHSL(C), TPLMFWH(C), LQFKHST(C), ATFRHST(C), TGLMFKH(C), AEFSHWH(C), QSEFKHW(C), AEFMHSVC(C), ADHDFRH(C), DGLLFKH(C), MFRHDS(C), SNSEFRR(C), SELRHST(C), THMEFRR(C), EELRHSV(C), QLFKHSP(C), YEFRHAQ(C), SNFRHSV(C), APIQFRH(C), AYFPHTS(C), NSSELRH(C), TEFRHKA(C), TSTEMWH(C), SQSYFKH(C), (C)SEFKH, SEFKH(C), (C) HEFRH i HEFRH (C), naznačena time, da je za proizvodnju lijeka za sprečavanje i/ili liječenje β-amiloidoze.
7. Uporaba prema zahtjevu 6, naznačena time, da spoj sadrži peptid koji ima aminokiselinsku sekvencu odabranu iz skupine koju čine: QDFRHY(C), SEFKHG(C), TSFRHG(C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHC(C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), SPNQFRH(C), TLHEFRH(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), DGLLFKH(C), EELRHSV(C), TEFRHKA(C), (C)SEFKH, SEFKH(C), (C)HEFRH i HEFRH(C), poželjno SEFKHG(C), TSVFRH(C), SQFRHY(C), LMFRHN(C), ILFRHG(C), SPNQFRH(C), ELFKHHL(C), TLHEFRH(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), YEFRHAQ(C), TEFRHKA(C).
8. Uporaba prema bilo kojem od zahtjeva 1 do 7, naznačena time, da navedeni spoj je polipeptid koji sadrži 4 do 20 aminokiselinskih ostataka.
9. Uporaba prema bilo kojem od zahtjeva 1 do 8, naznačena time, da spoj je vezan na farmaceutski prihvatljiv nosač, poželjno KLH (Keyhole Limpet Hemocyanin).
10. Uporaba prema bilo kojem od zahtjeva 1 do 9, naznačena time, da spoj je formuliran za intravenoznu, subkutanu, intradermalnu ili intramuskularnu primjenu.
11. Uporaba prema bilo kojem od zahtjeva 1 do 10, naznačena time, da spoj je formuliran s pomoćnim sredstvom, poželjno s aluminijskim hidroksidom.
12. Uporaba prema bilo kojem od zahtjeva 1 do 11, naznačena time, da spoj je u sastavu lijeka u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, posebno od 100 ng to 100 μg.
13. Uporaba spoja prema bilo kojem od zahtjeva 1 do 10, naznačena time, da je za liječenje i/ili poboljšavanje simptoma sinukleinopatije.
14. Uporaba prema zahtjevu 13, naznačena time, da sinukleinopatija je odabrana iz sljedeće skupine: Parkinsonova bolest, demencija s Lewyjevim tjelešcima, višestruka atrofija sustava i neurodegeneracija s akumuliranjem željeza u mozgu.
15. Peptid, naznačen time, da ima aminokiselinsku sekvencu odabranu iz skupine koju čine: IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C), IRWDGG(C), EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRG(C), EVWHRH(C), ERWHEK(C), QDFRHY(C), SEFKHG(C), TSFRHG(C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHG (C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), NELRHST(C), GEMRHQP(C), DTYFPRS(C), VELRHSR(C), YSMRHDA(C), AANYFPR(C), SPNQFRH(C), SSSFFPR(C), EDWFFWH(C), SAGSFRH(C), QVMRHHA(C), SEFSHSS(C), QPNLFYH(C), ELFKHHL (C), TLHEFRH(C), ATFRHSP(C), APMYFPH(C), TYFSHSL(C), HEPLFSH(C), SLMRHSS(C), EFLRHTL(C), ATPLFRH(C), QELKRYY(C), THTDFRH(C), LHIPFRH(C), NELFKHF(C), SQYFPRP(C), DEHPFRH(C), MLPFRHG(C), SAMRHSL(C), TPLMFWH(C), LQFKHST(C), ATFRHST(C), TGLMFKH(C), AEFSHWH(C), QSEFKHW(C), AEFMHSV(C), ADHDFRH(C), DGLLFKH(C), IGFRHDS(C), SNSEFRR(C), SELRHST(C), THMEFRR(C), EELRHSV(C), QLFKHSP(C), YEFRHAQ(C), SNFRHSV(C), APIQFRH(C), AYFPHTS(C), NSSELRH(C), TEFRHKA(C), TSTEMWH(C), SQSYFKH(C), (C)SEFKH, SEFKH(C), (C)HEFRH i HEFRH(C).
16. Peptid prema zahtjevu 15, naznačen time, da je taj peptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
17. Farmaceutska formulacija, poželjno cjepivo, naznačeno time, da sadrži peptid prema zahtjevu 15 ili 16.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0095108A AT506819B1 (de) | 2008-06-12 | 2008-06-12 | Vakzin zur behandlung von alzheimer-krankheit |
| PCT/AT2009/000236 WO2009149486A2 (en) | 2008-06-12 | 2009-06-12 | Compounds for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140586T1 true HRP20140586T1 (hr) | 2014-09-12 |
Family
ID=41401982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140586AT HRP20140586T1 (hr) | 2008-06-12 | 2014-06-23 | Peptidi za lijeäśenje beta-amiloidoze |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8613931B2 (hr) |
| EP (1) | EP2310034B9 (hr) |
| JP (2) | JP2011522841A (hr) |
| KR (1) | KR20110036808A (hr) |
| CN (1) | CN102123727B (hr) |
| AT (3) | AT506819B1 (hr) |
| AU (1) | AU2009257169B2 (hr) |
| BR (1) | BRPI0915137A2 (hr) |
| CA (1) | CA2723991A1 (hr) |
| CY (1) | CY1115316T1 (hr) |
| DK (1) | DK2310034T3 (hr) |
| ES (1) | ES2461492T3 (hr) |
| HK (1) | HK1152470A1 (hr) |
| HR (1) | HRP20140586T1 (hr) |
| IL (1) | IL209895A (hr) |
| MX (1) | MX2010013648A (hr) |
| PL (1) | PL2310034T3 (hr) |
| PT (1) | PT2310034E (hr) |
| RS (1) | RS53236B (hr) |
| RU (1) | RU2553345C2 (hr) |
| SI (1) | SI2310034T1 (hr) |
| WO (1) | WO2009149486A2 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| WO2012172427A2 (en) * | 2011-06-14 | 2012-12-20 | National Taiwan University | Peptide compounds for inhibition of platelet aggregation |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| ES2496341T3 (es) | 2011-10-04 | 2014-09-18 | Affiris Ag | Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica |
| EP2659908A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2787347A1 (en) | 2013-04-03 | 2014-10-08 | Affiris AG | Method for detecting Aß-specific antibodies in a biological sample |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| ES2953381T3 (es) * | 2014-04-29 | 2023-11-13 | Advantage Therapeutics Inc | Tratamiento y prevención de la enfermedad de Alzheimer (AD) |
| WO2015165968A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2017079835A1 (en) * | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
| EP3374379A4 (en) * | 2015-11-09 | 2019-05-15 | The University Of British Columbia | N-TERMINAL EPITOPES IN BETA-AMYLOID AND CONFORMATIONALLY SELECTIVE ANTIBODIES THEREOF |
| US10774120B2 (en) * | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| KR102554448B1 (ko) * | 2016-06-29 | 2023-07-11 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 알파-시누클레인 응집의 구조-기반 펩타이드 저해제 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| CN109985231A (zh) * | 2018-01-02 | 2019-07-09 | 上海清流生物医药科技有限公司 | 一种蛋白在制备预防和治疗痴呆症的药物中的应用 |
| IL301223A (en) * | 2020-09-17 | 2023-05-01 | Othair Prothena Ltd | Beta-amyloid vaccine for the treatment of Alzheimer's disease |
| CN112608926A (zh) * | 2020-12-08 | 2021-04-06 | 安徽大千生物工程有限公司 | 一种用于检测β淀粉样蛋白的基因序列组、杂交瘤细胞组及胶乳增强免疫比浊法试剂盒 |
| CN113061161B (zh) * | 2021-04-02 | 2023-09-12 | 河南省农业科学院动物免疫学重点实验室 | 靶向amyloid-beta结构的抑制性肽配基及应用 |
| WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| RU2294211C2 (ru) * | 2001-01-19 | 2007-02-27 | Цитос Байотекнолоджи Аг | Композиция и способ для иммунизации, способ продуцирования неприродного, упорядоченного и повторяющегося массива антигенов |
| US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
| AT413945B (de) * | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005023985A2 (en) * | 2003-09-03 | 2005-03-17 | University Of Rochester | Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof |
| US20050176030A1 (en) | 2003-10-28 | 2005-08-11 | Li Gan | Regulated nucleic acids in pathogenesis of Alzheimer's Disease |
| AT413946B (de) * | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| GB0421639D0 (en) | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| CA2584859C (en) | 2004-10-25 | 2017-11-07 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
| EP2397852B1 (en) * | 2006-03-14 | 2013-12-04 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| WO2008002893A2 (en) | 2006-06-29 | 2008-01-03 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| US20120017338A1 (en) * | 2008-01-15 | 2012-01-19 | Wei Wu | Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits |
-
2008
- 2008-06-12 AT AT0095108A patent/AT506819B1/de not_active IP Right Cessation
-
2009
- 2009-06-12 WO PCT/AT2009/000236 patent/WO2009149486A2/en active Application Filing
- 2009-06-12 CN CN200980131375.9A patent/CN102123727B/zh not_active Expired - Fee Related
- 2009-06-12 CA CA2723991A patent/CA2723991A1/en not_active Abandoned
- 2009-06-12 RS RS20140145A patent/RS53236B/en unknown
- 2009-06-12 MX MX2010013648A patent/MX2010013648A/es active IP Right Grant
- 2009-06-12 BR BRPI0915137A patent/BRPI0915137A2/pt not_active IP Right Cessation
- 2009-06-12 DK DK09761153.7T patent/DK2310034T3/da active
- 2009-06-12 KR KR1020117000814A patent/KR20110036808A/ko not_active Application Discontinuation
- 2009-06-12 US US12/997,674 patent/US8613931B2/en not_active Expired - Fee Related
- 2009-06-12 SI SI200930901T patent/SI2310034T1/sl unknown
- 2009-06-12 PL PL09761153T patent/PL2310034T3/pl unknown
- 2009-06-12 PT PT97611537T patent/PT2310034E/pt unknown
- 2009-06-12 JP JP2011512781A patent/JP2011522841A/ja active Pending
- 2009-06-12 RU RU2011100126/15A patent/RU2553345C2/ru not_active IP Right Cessation
- 2009-06-12 EP EP09761153.7A patent/EP2310034B9/en active Active
- 2009-06-12 AU AU2009257169A patent/AU2009257169B2/en not_active Ceased
- 2009-06-12 ES ES09761153.7T patent/ES2461492T3/es active Active
- 2009-12-11 AT AT0196409A patent/AT509106B1/de not_active IP Right Cessation
- 2009-12-11 AT AT0196309A patent/AT509105B1/de not_active IP Right Cessation
-
2010
- 2010-12-09 IL IL209895A patent/IL209895A/en not_active IP Right Cessation
-
2011
- 2011-06-22 HK HK11106465.0A patent/HK1152470A1/xx not_active IP Right Cessation
-
2013
- 2013-03-15 US US13/838,152 patent/US20130230545A1/en not_active Abandoned
-
2014
- 2014-06-23 HR HRP20140586AT patent/HRP20140586T1/hr unknown
- 2014-06-23 CY CY20141100458T patent/CY1115316T1/el unknown
-
2015
- 2015-03-04 JP JP2015042921A patent/JP6041917B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140586T1 (hr) | Peptidi za lijeäśenje beta-amiloidoze | |
| HRP20160594T1 (hr) | Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima | |
| RU2011100125A (ru) | Соединения для лечения амилоидозов | |
| HRP20151148T1 (hr) | Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja | |
| RU2016120641A (ru) | Новые полипептиды | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| RU2013154066A (ru) | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения | |
| JP2011522842A5 (hr) | ||
| WO2009034134A3 (en) | Use of natriuretic peptides for treating angioedema syndromes | |
| RU2015143472A (ru) | Конъюгаты инсулин-инкретин | |
| HRP20141215T1 (hr) | Analozi oksintomodulina | |
| AR072009A1 (es) | Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos | |
| UA103154C2 (uk) | Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його | |
| EP2508601A3 (en) | Tem8 peptides and vaccines comprising the same | |
| JP2016500682A5 (hr) | ||
| WO2007144198B1 (en) | Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| WO2005074626A3 (en) | Compositions, methods and uses for a novel family of peptides | |
| JP2007535910A5 (hr) | ||
| RU2010111139A (ru) | Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства | |
| JP2006506942A5 (hr) | ||
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| JP2009510134A5 (hr) | ||
| MX2016011852A (es) | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). | |
| JP2009533355A5 (hr) |